Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1/2 trial
Justin M. Watts, Maria R. Baer, Jay Yang, Thomas Prébet, Sang‐Min Lee, Gary J. Schiller, Shira Dinner, Arnaud Pigneux, Pau Montesinos, Eunice S. Wang, Karen Seiter, Andrew H. Wei, Stéphane de Botton, Montserrat Arnán, Will Donnellan, Anthony P. Schwarer, Christian Récher, Brian A. Jonas, P. Brent Ferrell, Christophe Marzac, Patrick Kelly, Jennifer Sweeney, Sanjeev Forsyth, Sylvie M. Guichard, Julie Brevard, Patrick Henrick, Hesham Mohamed, Jörge E. Cortes
Topics & Concepts
MedicineAzacitidineMyelodysplastic syndromesInternal medicinePharmacodynamicsPharmacokineticsMyeloidPhases of clinical researchIDH1Clinical trialGastroenterologyOncologyBone marrowGene expressionMutationChemistryBiochemistryGeneDNA methylationAcute Myeloid Leukemia ResearchBiochemical and Molecular ResearchBlood disorders and treatments